These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6537969)

  • 21. Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists.
    Hruska RE
    Brain Res Bull; 1986 Mar; 16(3):331-9. PubMed ID: 3708389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Striatal dopamine receptor supersensitivity after long-term haloperidol treatment of hypophysectomized rats.
    DeLucia R; Scavone C; Camillo MA
    Braz J Med Biol Res; 1989; 22(6):741-3. PubMed ID: 2620186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
    Gulati A; Srimal RC; Dhawan BN
    Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrastriatal injection of kainic acid prevents the development of postsynaptic dopamine receptor hypersensitivity after chronic haloperidol treatment.
    Zarkovsky AM; Nurk AM; Rägo LK; Allikmets LH
    Neuropharmacology; 1982 Feb; 21(2):155-8. PubMed ID: 7199630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of estrogens on striatal dopaminergic activity.
    Ramos JA; Pais JR; Cebeira M; Fernandez-Ruiz J
    J Steroid Biochem; 1987; 27(4-6):683-9. PubMed ID: 2961941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
    Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
    Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.
    Reches A; Wagner HR; Barkai AI; Jackson V; Yablonskaya-Alter E; Fahn S
    Psychopharmacology (Berl); 1984; 83(2):155-8. PubMed ID: 6431465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
    Pierce RC; Rowlett JK; Bardo MT; Rebec GV
    Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic autoreceptor blockade and neuroleptic-induced dopamine receptor hypersensitivity.
    Gordon JH; Clopton JK; Curtin JC; Koller WC
    Pharmacol Biochem Behav; 1987 Feb; 26(2):223-8. PubMed ID: 3575347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The possible role of 2-hydroxyestradiol in the development of estrogen-induced striatal dopamine receptor hypersensitivity.
    Clopton JK; Gordon JH
    Brain Res; 1985 Apr; 333(1):1-10. PubMed ID: 2986765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of the intracaudate administration of kainic acid on the effects of the prolonged use of haloperidol and apomorphine on rats].
    Zharkovskiĭ AM; Allikmets LKh; Nurk AM
    Farmakol Toksikol; 1982; 45(1):10-2. PubMed ID: 7198997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolactin increases the density of striatal dopamine receptors in normal and hypophysectomized male rats.
    Hruska RE; Pitman KT; Silbergeld EK; Ludmer LM
    Life Sci; 1982 Feb; 30(6):547-53. PubMed ID: 7070218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypophysectomy prevents the striatal dopamine receptor supersensitivity produced by chronic haloperidol treatment.
    Hruska RE; Ludmer LM; Silbergeld EK
    Eur J Pharmacol; 1980 Aug; 65(4):455-6. PubMed ID: 7408951
    [No Abstract]   [Full Text] [Related]  

  • 34. During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated.
    Dyer RG; Murugaiah K; Theodorou A; Clow A; Jenner P; Marsden CD
    Life Sci; 1981 Jan; 28(2):167-74. PubMed ID: 6114373
    [No Abstract]   [Full Text] [Related]  

  • 35. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity?
    Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E
    Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat.
    Kinon BJ; Merson D; Kane JM
    Psychopharmacology (Berl); 1984; 84(3):347-51. PubMed ID: 6440181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible dissociation of central dopamine receptor antagonism and cataleptic behavior.
    Hruska RE
    Pharmacol Biochem Behav; 1985 Nov; 23(5):789-95. PubMed ID: 4080765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
    Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
    Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypophysectomy-induced striatal hypersensitivity and mesolimbic hyposensitivity to apomorphine.
    Gordon JH
    Pharmacol Biochem Behav; 1983 Nov; 19(5):807-11. PubMed ID: 6139829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.